Regulatory Approval in Singapore Opens New Pathways for Earlier, More Accessible Diabetes Diagnosis
Regulatory Approval in Singapore Opens New Pathways for Earlier, More Accessible Diabetes Diagnosis
NHS Hospital Trust Pilot of New Testing Technology Sees Pregnant Women in Southampton Become the First Patients Globally to Access Gestational Diabetes Testing at Home.
NHS Hospital Trust Pilot of New Testing Technology Sees Pregnant Women in Southampton Become the First Patients Globally to Access Gestational Diabetes Testing at Home.
Oxford, United Kingdom 18/12/2025 – Diabetes remains one of the fastest-growing public health challenges in Singapore, with around one in nine adults now living with the condition and almost 30% of pregnant women developing gestational diabetes. Early and accurate diagnosis is critical to preventing long-term complications, yet traditional clinic-based glucose tolerance testing creates barriers for both patients and health systems - from appointment availability to delays in sample handling.
-1.png?width=350&height=310&name=Stock%20Image%20-%20Focus%20Group%20-%20Test%202%20+%20Blue%20Tramline%20-%20Left%20and%20Right%20(5)-1.png "Stock Image - Focus Group - Test 2 + Blue Tramline - Left and Right (5)-1")
Against this backdrop, Digostics has received regulatory approval from Singapore’s Health Sciences Authority (HSA) for its home-based glucose tolerance testing solution. The approval enables Digostics to begin clinical pilots and research collaborations with healthcare partners in Singapore, supporting the evaluation of more flexible, patient-centred approaches to diabetes diagnosis across both public and private care settings. Digostics’ GTT@home enables clinically robust glucose tolerance testing to be carried out remotely, helping to address practical challenges such as travel, time away from work, and time-sensitive sample processing. By improving access to testing while maintaining diagnostic integrity, home-based models have the potential to support earlier detection and reduce avoidable pressure on clinics and hospitals.
HSA approval allows Digostics to work with local clinical partners to assess real-world usability, patient experience and clinical performance across multiple diabetes pathways. This work builds on Digostics’ existing experience supporting gestational diabetes and cystic fibrosis–related diabetes testing in the UK, alongside type 1 diabetes research programmes in Europe and the United States.
“This approval allows us to start working directly with clinicians in Singapore to explore how more accessible diagnostic pathways could support earlier detection and better outcomes,” said Lewis Owens, CEO of Digostics Asia. “Singapore’s focus on prevention and innovation makes it an ideal environment to evaluate new testing models that are designed around patients as well as clinical standards.”
Singapore represents the first regulatory step in Digostics’ wider Asia-Pacific strategy, with further regional expansion planned as clinical evidence and partnerships develop. Across all markets, the company’s approach prioritises collaboration with healthcare systems to ensure diagnostic pathways are clinically robust, equitable and scalable. By enabling earlier and more accessible diagnosis, Digostics aims to support better outcomes for people living with diabetes and those at risk. Helping to reduce preventable complications while easing pressure on healthcare services.
"We hope this revolutionary new at-home test is going to dramatically change the way we deliver gestational diabetes testing during antenatal care."
Dr Matthew Coleman
Click the button below for more GTT@home product-specific information exploring:
• the GTT@home test kit's contents
• the novel GTT@home test device
• at-home versus in-clinic test comparisons
• patient and healthcare professional support
Click the button below for more GTT@home product-specific information exploring:
• the GTT@home test kit's contents
• the novel GTT@home test device
• at-home versus in-clinic test comparisons
• patient and healthcare professional support
About Digostics
Far too many people across the world are living with undiagnosed diabetes.
UK-based Digostics' mission is to enable healthcare providers to identify everyone with diabetes, and those at risk of developing diabetes, by eliminating the common barriers that inhibit accurate and timely testing using the gold standard oral glucose tolerance test (OGTT).
Digostics is proud to offer GTT@home - the world’s first home OGTT offering and the most accessible and scalable way for clinical teams to realise their diabetes testing objectives.
To learn more, visit www.digostics.com
About University Hospital NHS Foundation Trust
University Hospital Southampton NHS Foundation Trust provides services to some 1.9 million people living in Southampton and south Hampshire, plus specialist services such as neurosciences, cardiac services and children's intensive care to more than 3.7 million people in central southern England and the Channel Islands.
UHS is one of the largest acute teaching trusts in England with a staff of 13,000 and a turnover of more than £1bn in 2020/21.
We are one of only two major trauma centres in the South of England for both adults and children.
UHS is consistently one of the UK’s highest recruiting trusts of patients to clinical trials.
Could GTT@home be of assistance to your patients?
Please get in touch by completing the form below or calling us on +44 (0)330 113 9145.
References
¹ International Diabetes Federation - Diabetes Atlas 10th Edition 2021
² NHS Gestational Diabetes Overview
³ International Diabetes Federation - Care and Prevention - Gestational Diabetes
† Pubmed - Future risk of diabetes in mother and child after gestational diabetes mellitus 2009
Images of Matthew Coleman and of University Hospital Southampton's premises are kindly provided by University Hospital Southampton NHS Foundation Trust.